🔍

Ishita Drugs & Industries Ltd (524400)

📊 BSE: 524400 🏢 Pharmaceuticals 📢 Latest filing: 22 Sep 2026

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Ishita Drugs' revenue was ₹3.1 Cr (-41.8% year on year, +2.8% on the previous quarter), and net profit ₹0.2 Cr (-23.3% year on year); the operating margin was 10.1%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹3.1	-41.8%	+2.8%
Operating profit	₹0.3	-6.4%	+218.4%
Net profit	₹0.2	-23.3%	+27.9%
EPS (₹)	0.77	-23.0%	+28.3%
Operating margin	10.1%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

Ishita Drugs secures Rs 11.75 Cr credit facilities from HDFC Bank for Schedule M capex

🟢 POSITIVE ⭐ 9/10

EXPANSION 📅 22 Sep 2026, 05:51 PM

Ishita Drugs & Industries has entered into a loan agreement with HDFC Bank Limited to avail credit facilities totaling Rs 11.75 crore. The financing includes a term loan of Rs 9.75 crore and a working capital facility of Rs 2.00 crore. The funds are earmarked for upgrading its manufacturing facility at Sanand, Gujarat, to comply with Revised Schedule M standards. At Rs 11.75 crore, this debt facility is highly material, representing nearly 98% of its TTM revenue of Rs 12 crore and about 98% of its net worth of Rs 12 crore.

Total credit facility of Rs 11.75 crore executed with HDFC Bank on 22.09.2026
Facility comprises a Rs 9.75 crore term loan and a Rs 2.00 crore working capital limit
Proceeds to fund plant upgradation to meet Revised Schedule M pharma compliance at Sanand, Gujarat
Secured by a first charge on immovable and movable assets at Sanand facility; current outstanding is Nil

💡 Track the deployment schedule of the capex, completion timelines for the Revised Schedule M upgrades, and the impact of subsequent interest costs on quarterly margins.

Ishita Drugs Approves ₹11.75 Cr Borrowing from HDFC Bank (Nearly 100% of TTM Revenue)

🔵 WATCH ⭐ 9/10

FUNDRAISE 📅 22 Sep 2026, 03:27 PM

Ishita Drugs & Industries Ltd has approved credit facilities totaling ₹11.75 crore from HDFC Bank Ltd. The borrowing comprises a term loan of ₹9.75 crore and a working capital facility of ₹2.00 crore based on HDFC Bank's sanction letter dated September 17, 2026. This is a very significant leverage increase for the micro-cap pharma company, as the facility represents roughly 98% of its TTM revenue (₹12 crore) and matches its net worth of ₹12 crore, shifting its previously debt-free balance sheet.

Total borrowing approved: ₹11,75,00,000 (₹11.75 crore) from HDFC Bank Limited
Facility split: ₹9,75,00,000 (₹9.75 crore) Term Loan and ₹2,00,00,000 (₹2.00 crore) Working Capital
Terms governed by HDFC Bank's Sanction Letter dated September 17, 2026
Borrowing is within limits approved under Section 180(1)(c) at AGM held on September 30, 2024

💡 Watch for disclosures on the exact end-use of the ₹9.75 crore term loan (such as capex or facility modernization) and monitor interest cost impacts on net margins in future quarters.

Ishita Drugs Dispatches AGM Notice & FY26 Annual Report Weblink Letters to Shareholders

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 31 Aug 2026, 02:32 PM

Ishita Drugs & Industries Ltd has issued letters providing the weblink to its FY2025-26 Annual Report and AGM Notice to shareholders without registered email addresses. The company's 33rd Annual General Meeting is scheduled to be held on Wednesday, September 30, 2026, at 11:30 AM in Sanand, Gujarat. Physical dispatches to unregistered shareholders were completed via courier on August 27, 2026, based on the record cut-off date of August 21, 2026.

33rd Annual General Meeting scheduled for September 30, 2026, at 11:30 AM
Letters containing the FY26 Annual Report weblink dispatched to unregistered shareholders on August 27, 2026
Shareholder email registration record cut-off date fixed as August 21, 2026

💡 Shareholders holding physical shares or unregistered emails can update their KYC details with Bigshare Services Pvt. Ltd. and review the AGM agenda ahead of the September 30, 2026 meeting.

Ishita Drugs Submits FY26 Annual Report, Schedules 33rd AGM for Sep 30, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 27 Aug 2026, 04:01 PM

Ishita Drugs & Industries Ltd has submitted its Annual Report for FY 2025-26 pursuant to Regulation 34 of SEBI LODR Regulations. The 33rd Annual General Meeting (AGM) is scheduled for September 30, 2026, at Sanand, Gujarat. The key agenda items include the adoption of FY26 financial statements, re-appointment of the statutory auditor, re-appointment of director Mrs. Abha Agrawal, and approval of material related-party transactions exceeding 10% of annual turnover with Ishita Pharmaceuticals and Anvi Lifesciences.

33rd Annual General Meeting scheduled for September 30, 2026, at 11:30 AM
Register of Members and Share Transfer books to remain closed from September 24, 2026, to September 30, 2026
Seeking shareholder approval for related-party transactions exceeding 10% of annual turnover with Ishita Pharmaceuticals and Anvi Lifesciences Private Limited
Proposed re-appointment of M/s Jaymin Shah & Associates as statutory auditors for one year

💡 Track shareholder voting outcomes on AGM resolutions post September 30, 2026, particularly regarding the material related-party transactions.

Ishita Drugs Schedules 33rd AGM on Sep 30, 2026; E-Voting Cut-Off Set for Sep 23, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 27 Aug 2026, 03:54 PM

Ishita Drugs & Industries Ltd has announced that its 33rd Annual General Meeting (AGM) will be held on Wednesday, September 30, 2026. The company has fixed September 23, 2026, as the cut-off date to determine shareholder voting entitlement. The remote e-voting window will be facilitated via NSDL and will run from September 27, 2026 (9:00 AM IST) to September 29, 2026 (5:00 PM IST).

33rd Annual General Meeting scheduled for September 30, 2026
Record/cut-off date for e-voting eligibility fixed as September 23, 2026
E-voting window opens September 27, 2026 (09:00 AM IST) and closes September 29, 2026 (05:00 PM IST)
Remote e-voting platform to be provided by NSDL

💡 Eligible shareholders holding shares on September 23, 2026, should review the AGM agenda resolutions and cast their votes during the September 27–29 window.

Ishita Drugs & Industries Schedules 33rd AGM on Sep 30, 2026; E-Voting from Sep 27

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 27 Aug 2026, 03:47 PM

Ishita Drugs & Industries Ltd has announced the schedule and cut-off dates for its 33rd Annual General Meeting (AGM) scheduled for September 30, 2026. The cut-off date to determine shareholder voting entitlement is fixed as September 23, 2026. Remote e-voting via NSDL will start on September 27, 2026 (09:00 AM IST) and close on September 29, 2026 (05:00 PM IST). This is a standard statutory compliance filing under SEBI LODR Regulation 44.

33rd Annual General Meeting scheduled for September 30, 2026
Cut-off date for e-voting eligibility set as September 23, 2026
E-voting period runs from September 27, 2026 (09:00 AM IST) to September 29, 2026 (05:00 PM IST)
E-voting platform services to be provided by NSDL

💡 Eligible shareholders holding shares on September 23, 2026, can cast their votes on AGM resolutions between September 27 and September 29, 2026.

Ishita Drugs & Industries Schedules 33rd AGM on Sep 30, 2026; Book Closure from Sep 24

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 27 Aug 2026, 03:40 PM

Ishita Drugs & Industries Ltd has announced its 33rd Annual General Meeting (AGM) scheduled for September 30, 2026, at 11:30 AM in Sanand, Gujarat. The Register of Members and Share Transfer Books will remain closed from September 24, 2026, to September 30, 2026 (both days inclusive) for AGM purposes. The integrated annual report and notice of AGM will be dispatched in due course.

33rd Annual General Meeting scheduled for September 30, 2026, at 11:30 AM
Book closure period set from September 24, 2026, to September 30, 2026 (both days inclusive)
Meeting venue: 'Manthan', Hotel Krsna Lila, Sanand Viramgam Highway, Gujarat

💡 Shareholders should look out for the upcoming dispatch of the full Annual Report and AGM Notice for details on operational performance and voting resolutions.

Ishita Drugs Commits Rs 10 Cr to Facility Upgradation; Re-appoints Director

🟢 POSITIVE ⭐ 8/10

EXPANSION 📅 08 Aug 2026, 03:47 PM

Ishita Drugs has announced a major manufacturing facility upgradation to comply with Revised Schedule M standards, involving a total commitment of approximately Rs 10 crore. To date, the company has spent Rs 4.35 crore on civil works and a new warehouse, with another Rs 5.65 crore in equipment orders issued. This project is highly material, representing approximately 67% of the company's TTM revenue of Rs 15 crore and 83% of its net worth. The board also approved the re-appointment of promoter Mrs. Abha Agrawal as a director and is currently negotiating with banks for project financing.

Rs 4.35 crore already spent on renovation of existing buildings and construction of a new warehouse block.
Rs 5.65 crore in capital contracts and orders issued for various utilities and equipment.
Total project commitment of ~Rs 10 crore represents ~67% of TTM revenue (Rs 15 Cr).
Re-appointment of Mrs. Abha Agrawal as Non-Executive Director notwithstanding her attaining the age of 75 years.
Company is actively negotiating with banks to raise funds for financing the remaining upgradation project.

💡 Monitor the successful closure of bank financing for the project and the timeline for completion of the manufacturing facility extension to ensure no regulatory disruptions.

Rs 10 Cr Capex for Facility Upgradation; Q1 FY27 Results Approved

🟢 POSITIVE ⭐ 8/10

EXPANSION 📅 08 Aug 2026, 03:43 PM

Ishita Drugs & Industries has announced a major manufacturing facility upgradation project to comply with Revised Schedule M standards. The company has already spent Rs 4.35 crore on renovation and new construction, with an additional Rs 5.65 crore in capital contracts already issued. This total commitment of Rs 10 crore is highly significant, representing approximately 67% of the company's TTM revenue of Rs 15 crore. The company is currently negotiating with banks to secure financing for the project.

Rs 4.35 crore already spent on renovation of existing buildings and construction of new blocks
Rs 5.65 crore in capital contracts and orders issued for utilities and equipment
Total project visibility of Rs 10 crore represents ~67% of TTM revenue (Rs 15 cr)
Upgradation project is aimed at compliance with Revised Schedule M manufacturing standards
Board approved re-appointment of promoter Mrs. Abha Agrawal as Non-Executive Director

💡 Monitor the successful closure of bank financing and the timeline for the completion of the manufacturing facility upgrade. Watch for any impact on production during the renovation phase in upcoming quarterly results.

Ishita Drugs to invest ₹10 Cr in facility upgrade; ₹4.35 Cr already spent

🟢 POSITIVE ⭐ 8/10

EXPANSION 📅 08 Aug 2026, 03:35 PM

Ishita Drugs & Industries has announced a significant manufacturing facility upgrade to comply with Revised Schedule M standards. The company has already spent ₹4.35 crore on construction and has issued capital contracts worth ₹5.65 crore for equipment and utilities. This total project outlay of ₹10 crore is highly material, representing approximately 67% of the company's TTM revenue of ₹15 crore. The board also approved Q1 FY27 results and is currently negotiating with banks to secure funding for the project.

₹435 lakh (₹4.35 cr) already spent towards renovation and construction of new blocks
₹565 lakh (₹5.65 cr) in capital contracts and orders issued for utilities and equipment
Total project visibility of ₹10 cr represents ~67% of TTM revenue and ~43% of market cap
Construction of a new warehouse block has been completed as part of the ongoing upgrade
Board approved re-appointment of promoter-director Mrs. Abha Agrawal post attaining age 75

💡 Watch for the successful closure of bank financing negotiations and the completion timeline for the remaining civil works on existing buildings.

Ishita Drugs to consider Q1 FY27 results on August 8, 2026

🟡 NEUTRAL ⭐ 3/10

BOARD_MEETING 📅 31 Jul 2026, 01:56 PM

Ishita Drugs & Industries Ltd has scheduled a board meeting for August 8, 2026, to approve its unaudited financial results for the quarter ended June 30, 2026. The company is a micro-cap with a market capitalization of Rs 22 Cr and TTM revenue of Rs 15 Cr. Investors will be monitoring for a potential recovery in quarterly revenue, which declined from Rs 5.4 Cr in June 2025 to Rs 3.06 Cr in March 2026. The trading window for designated persons has been closed since July 1, 2026, as per SEBI regulations.

Board meeting scheduled for August 8, 2026, to approve Q1 FY27 results
Trading window closed from July 1, 2026, until 48 hours after result declaration
Company reported TTM revenue of Rs 15 Cr and TTM PAT of Rs 1 Cr
Operating profit margin (OPM) stands at 5.2% as per latest annual data
Promoter holding remains stable at 50.04% as of June 2026

💡 Watch for the earnings release on August 8 to see if the company can improve its quarterly revenue run-rate, which has stagnated around Rs 3 Cr for the last three quarters.

View All 524400 Announcements on Live Market Tracking →